Spyre Therapeutics (SYRE) total liabilities

Total liabilities · fiscal 2025
$62.55M

Spyre Therapeutics (SYRE) had total liabilities of $62.55M at the end of fiscal 2025 (December 31, 2025). That is 31.0% lower than the $90.68M of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$62.55M
Change on fiscal 2024
−31.0%
Growth, 5 years
+23.5% a year
Growth, 10 years
+37.7% a year
Highest on record
$157.84Mfiscal 2023
Lowest on record
$2.55Mfiscal 2015
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Spyre Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 23.5% a year; over ten years the rate was 37.7% a year. Across the 11 fiscal years on record (2015–2025), the highest was $157.84M in fiscal 2023 and the lowest $2.55M in fiscal 2015.

History · 11 fiscal years

Total liabilities by fiscal year

Spyre Therapeutics total liabilities, year by year

Spyre Therapeutics (SYRE) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$62.55M 31.0% down
2024$90.68M 42.6% down
2023$157.84M 657.4% up
2022$20.84M 19.8% down
2021$25.99M 19.3% up
2020$21.79M 5.7% down
2019$23.10M 124.1% up
2018$10.31M 79.6% up
2017$5.74M 40.1% up
2016$4.10M 60.7% up
2015$2.55M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Spyre Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
Vaxcyte PCVX$317.21M2025
Bio-Rad Laboratories BIO$3.12B2025
Molina Healthcare MOH$11.50B2025
Spyre Therapeutics SYRE$62.55M2025
Qiagen QGEN$2.50B2025
Insulet PODD$1.68B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on SYRE

Spyre Therapeutics, figure by figure

Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value

Spyre Therapeutics total liabilities: questions and answers

How large are Spyre Therapeutics's total liabilities?

Spyre Therapeutics (SYRE) had total liabilities of $62.55M at the end of fiscal 2025 (December 31, 2025). That is 31.0% lower than the $90.68M of fiscal 2024.

What is the growth rate of Spyre Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 23.5% a year; over ten years the rate was 37.7% a year.

What are the highest and lowest total liabilities figures on record for Spyre Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was $157.84M in fiscal 2023 and the lowest $2.55M in fiscal 2015.

How is Spyre Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Spyre Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Spyre Therapeutics (SYRE) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.